Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02688270 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
A Phase 2 study of Raynaud's Phenomenon Secondary to Connective Tissue Disease, sponsored by Covis Pharma S.à.r.l..
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT02688270 is a Phase 2 study of Raynaud's Phenomenon Secondary to Connective Tissue Disease that has completed, run by Covis Pharma S.à.r.l.. The registered enrollment target is 65 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02688270, a Phase 2 study of Raynaud's Phenomenon Secondary to Connective Tissue Disease, has completed, sponsored by Covis Pharma S.à.r.l..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the ability of Vascana (0.9% nitroglycerin topical cream) to treat and prevent the symptoms experienced by subject's with Raynaud's Phenomenon. The symptoms of this disease include pain, tingling, and numbness in the fingers of the affected hand or hands.
Conditions Studied
Interventions
- DRUG Vascana (0.9% nitroglycerin cream)
- DRUG Vehicle Cream (placebo)
Study Locations (1)
Pennsylvania
- Multiple investigational sites - Multiple Locations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2016-06 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02688270
The ClinicalTrials.gov registry entry for NCT02688270 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Covis Pharma S.à.r.l., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Raynaud's Phenomenon Secondary to Connective Tissue Disease appearing as the primary indexed condition, and to 2 interventions - of which Vascana (0.9% nitroglycerin cream) is the first listed.
NCT02688270 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02688270 about?
NCT02688270 is a clinical study titled "Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon". The purpose of this study is to determine the ability of Vascana (0.9% nitroglycerin topical cream) to treat and prevent the symptoms experienced by subject's with Raynaud's Phenomenon. The symptoms of this disease include pain, tingling, and numbness in the fingers of the affected hand or hands.
What is the current status of trial NCT02688270?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2016-06. Estimated completion is 2016-12.
What conditions does trial NCT02688270 study?
This clinical trial studies the following conditions: Raynaud's Phenomenon Secondary to Connective Tissue Disease.
What interventions are being tested in trial NCT02688270?
The interventions under investigation include: Vascana (0.9% nitroglycerin cream) (DRUG), Vehicle Cream (placebo) (DRUG).
Who is sponsoring clinical trial NCT02688270?
This trial is sponsored by Covis Pharma S.à.r.l., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02688270 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.